Skip to content
DataLookout
Menu

NCT07836530

Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Eligibility criteria revised
    • Study sites: 0 to 2
    • Start date changed from estimate of Oct 2026 to Oct 23, 2026
    • Secondary endpoints: details revised at 1 of 8 entries
    • Study title revised
    • Study description expanded, about 3 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Overall Survival (OS)
Timeframe: Up to approximately 3.5 years

Secondary (8)

Overall Response Rate (ORR)
Duration of Response (DOR)
Progression Free Survival Rate (PFS)
Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (imAEs)
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Hepatocellular Carcinoma 18-question module [EORTC QLQ-HCC18]) Fatigue Scores
Show 3 moreShow less
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Function 17 (EORTC QLQ-F17) Global Health Status (GHS), and Physical/Role Functioning scores
Time to Deterioration of Fatigue Measured by EORTC QLQ-HCC18
Time to Deterioration of Global Health Status and Physical/Role Functioning Measured by EORTC QLQ-F17.

Arms and interventions

BGB-B2033Experimental

Participants are randomized to receive BGB-B2033 until disease progression, unacceptable toxicity, withdrawal of consent, death, or the end of the study, whichever occurs first.

Investigator's choice: Lenvatinib OR sorafenibActive comparator

Participants are randomized to receive either lenvatinib or sorafenib, selected by the investigator before treatment, until disease progression, unacceptable toxicity, withdrawal of consent, death, or the end of the study, whichever occurs first.

Drugs: BGB-B2033, Lenvatinib, Sorafenib

Sites

2 sites in 2 countries

Australia 1, New Zealand 1